Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01186419 · ClinicalTrials.gov registry record · Phase 2
Safety and Pharmacodynamic Study of an Oral Iron Chelator Given for 6 Months to Patients With Iron Overload
A Phase 2 study of Beta-Thalassemia and Transfusional Iron Overload, sponsored by Shire.
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
- 9
- Study locations
NCT01186419 is a Phase 2 study of Beta-Thalassemia and Transfusional Iron Overload that has completed, run by Shire. The registered enrollment target is 51 participants, below the 177-participant average among 14 other Beta-Thalassemia trials with a reported enrollment target (71% lower). The trial reports 9 study locations across 3 states.
The verdict
NCT01186419, a Phase 2 study of Beta-Thalassemia and Transfusional Iron Overload, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this research study is to evaluate the safety of two doses of FBS0701, a new oral iron chelator, and its effectiveness in clearing iron from the liver. FBS0701 is a medication taken by mouth that causes the body to get rid of iron. Iron chelators are used in patients with β-thalassemia and other forms of anemia who experience iron overload - iron increases in the body as a result of regularly required blood transfusions. Patients who qualify will be randomized to receive one of two doses of FBS0701 for up to 24 weeks (6 months) with a total study duration of up to 33 weeks. These patients will be eligible to participate in a dosing extension for up to 72 weeks. The maximum duration of dosing will be up to 96 weeks. The safety of patients will be monitored frequently during the study by physical exams, ECGs, and blood tests. To assess the amount of iron in the liver and heart, each patient must undergo 6 MRI scans during the study. Patients will not need to stay in the hospital for this study but will need to visit the outpatient clinic up to 28 times over the 96 week period. Patients currently taking an iron chelator will be required to stop for a total of up to 26 weeks. The results of this study will help to determine if FBS0701 may be effective as an iron chelator.
Conditions Studied
Interventions
- DRUG SPD602 (FBS0701, SSP-004184)
Study Locations (9)
Other
- Ospedale Regionale Microcitemie - Cagliari
- Centro della Microcitemia e delle Anemie Congenite - Genoa
- Thalassemia Center San Luigi Hospital - Orbassano
- Siriraj Hospital, Mahidol University - Bangkok
- Pediatric Hematology, Ege University Hospital - Izmir
- University College London Hospital - London
- Whittington Hospital - London
California
- Children's Hospital and Research Center of Oakland - Oakland
Massachusetts
- Children's Hospital of Boston - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2010-08-13 |
| Est. Completion | 2013-01-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01186419
The ClinicalTrials.gov registry entry for NCT01186419 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 177-participant average among 14 other Beta-Thalassemia trials with a reported enrollment target (71% lower). The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Beta-Thalassemia appearing as the primary indexed condition, and to 1 intervention - of which SPD602 (FBS0701, SSP-004184) is the first listed.
NCT01186419 reports 9 study locations spanning 3 distinct geographic areas - top geographies include Other, California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01186419 about?
NCT01186419 is a clinical study titled "Safety and Pharmacodynamic Study of an Oral Iron Chelator Given for 6 Months to Patients With Iron Overload". The purpose of this research study is to evaluate the safety of two doses of FBS0701, a new oral iron chelator, and its effectiveness in clearing iron from the liver. FBS0701 is a medication taken by mouth that causes the body to get rid of iron. Iron chelators are used in patients with β-thalassemi...
What is the current status of trial NCT01186419?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2010-08-13. Estimated completion is 2013-01-08.
What conditions does trial NCT01186419 study?
This clinical trial studies the following conditions: Beta-Thalassemia, Transfusional Iron Overload.
What interventions are being tested in trial NCT01186419?
The interventions under investigation include: SPD602 (FBS0701, SSP-004184) (DRUG).
Who is sponsoring clinical trial NCT01186419?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01186419 being conducted?
This trial has 9 study locations across California, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Beta-Thalassemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
RECRUITING · Phase 2
-
AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
RECRUITING · Phase 2
-
Stem Cell Transplant in Sickle Cell Disease and Thalassemia
ACTIVE NOT RECRUITING · Phase 2
-
Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia
COMPLETED · Phase 2
-
CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
COMPLETED · Phase 2
-
Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.